CUE vs. CRVS, PGEN, TNGX, TRVI, BTMD, SNDL, CMRX, YMAB, VYGR, and LFVN
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Corvus Pharmaceuticals (CRVS), Precigen (PGEN), Tango Therapeutics (TNGX), Trevi Therapeutics (TRVI), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry.
Cue Biopharma vs.
Cue Biopharma (NASDAQ:CUE) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
Corvus Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Corvus Pharmaceuticals' return on equity of -70.71% beat Cue Biopharma's return on equity.
Cue Biopharma currently has a consensus target price of $5.00, suggesting a potential upside of 281.68%. Corvus Pharmaceuticals has a consensus target price of $12.38, suggesting a potential upside of 147.01%. Given Cue Biopharma's higher probable upside, equities analysts clearly believe Cue Biopharma is more favorable than Corvus Pharmaceuticals.
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 12.3% of Cue Biopharma shares are held by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Cue Biopharma. Corvus Pharmaceuticals' average media sentiment score of 0.20 beat Cue Biopharma's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.
Corvus Pharmaceuticals has lower revenue, but higher earnings than Cue Biopharma. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Corvus Pharmaceuticals received 145 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote.
Summary
Corvus Pharmaceuticals beats Cue Biopharma on 12 of the 18 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CUE) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CUE Stock Alerts